Research Paper
Although antibiotics are among the most prescribed drugs in the world today and their development and commercialization have saved countless lives, the unmet need of efficacious drugs against bacteria is still high. Several bacterial infections such as diarrhoea, food poisoning, rheumatic fever, extra intestinal and intestinal wall infections are caused by multidrug resistant bacteria [1, 2] . This rapid rise in bacterial resistance towards available antibiotics is becoming a major threat to human health. Therefore, design of new class of compounds, with novel and distinct mode of action, from those of well-known classes, is of prime interest. Fungal infections pose a continuous and serious threat to human life. The severity of infection ranges from minor irritations such as athlete's foot to life-threatening systemic infections caused by Aspergillus fumigates [3] . Hence the development of a potent, safe and selective antifungal agent is of prime importance for medicinal chemist in the quest for effective chemotherapeutic treatment for fungal diseases [4] .
Tuberculosis is the leading cause of mortality from a single infectious agent and is responsible for more than three million deaths worldwide every year [5] . Despite half a century of antitubercular chemotherapy, there are still 8-10 million new cases of active tuberculosis each year and nearly two billion individuals are believed to harbour latent tuberculosis. In 2011, there were an estimated 8.7 million new cases of tuberculosis (13 % co-infected with HIV) and 1.4 million people died from tuberculosis [6] . One third of the world's population is currently infected and more than 5000 people die from tuberculosis everyday [7] . The synergy between tuberculosis and the AIDS epidemic as well as the surge of multidrug resistant isolates of Mycobacterium tuberculosis has reaffirmed tuberculosis as a primary
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public health threat. The current threat in TB treatment lies in the emergence of strains resistant to two of the best antitubercular drugs, isoniazid (INH) and rifampicin (RIF).
Triazole heterocycles is a building block of great value in drug candidates [8, 9] and a large number of ring systems containing this heterocyclic core have been incorporated into a wide variety of therapeutically interesting drug compounds including antiinflammatory, CNS stimulants, sedatives, antianxiety [10, 11] and antimycotic agents such as fluconazole, itraconazole and voriconazole [12, 13] . The 1,2,4-triazole, as well found to exhibit antiasthmatic [14] , antiviral (ribavirin) [15] , antifungal (fluconazole) [16] , antimicrobial [17, 18] , antibacterial [19] [20] [21] , insecticidal [22] , hypnotic [23] , cytotoxic [24] , antitubercular [25] and hypotensive [26, 27] activities. This moiety was also found in potent agonist and antagonist receptor ligands [28, 29] in HIV-1 protease inhibitors [30] and in thrombin inhibitors [31] .
Various isonicotinic acid derivatives like isonicotinyl hydrazides [32] , isonicotinamide derivatives [33] , 1,2,4-triazoles from isonicotinic acid hydrazide [34] , novel nalidixic acid derived 1,2,4-triazole [35] , 5-mercapto-1,2,4-triazole, novel 4H-1,2,4-triazol-3-yl-cycloalkanols [36] , new imidazole and 1,2,4-triazole substituted fluorobenzimidazoles [37] , and diphenylamine containing 1,2,4-triazoles [38] , have been reported to possess diverse activity including antimicrobial and antitubercular. The therapeutic potential of 1,2,4-triazole prompted us to synthesize new compounds in which substituent could be arranged in a pharmacophoric pattern to display high order of antimycobacterial activity.
Driven by the findings of above documented literature, an attempt was made to incorporate various structural components to derive a novel pharmacologically active core so as to explore its potential further for antitubercular effect. The current study is such an attempt, in which 1,2,4-triazoles were synthesized and evaluated as antitubercular agents. The hypothesis was to join pyridine component of INH and Schiff base structure with the emerging antitubercular 1,2,4-triazole framework in these target compounds. The thiol group (-SH) has been introduced in the target compounds with the view that it could help binding to the cationic functional group or metal ion in the active site of the target. The compounds attempted to synthesize were given in fig. 1 . Synthesized compounds were screened against sensitive and resistant M. tuberculosis strains. Additionally, these synthesized compounds were also tested in vitro for antibacterial, antifungal activities against various strains.
MATERIALS AND METHODS
The chemicals used for the experimental work were of synthetic grade (CDH, HiMedia, Rankem) and were used without further purification. Reactions were monitored by thin layer chromatography (TLC) on precoated silica gel-G glass plates using methanol and ethyl acetate in 3:7 ratio as mobile phase and the spots were visualized by iodine vapour. Melting points of synthesized compounds were determined by open glass capillary method and were uncorrected. Infrared (IR) spectra were recorded on Shimadzu FT-IR and Perkin-Elmer FT-IR spectrophotometer as KBr pellet and values are expressed as υ max cm -1 .
1 H and
13
C nuclear magnetic resonance spectroscopy (NMR) spectral analysis of the synthesized compounds were recorded on a Bruker Avance III 500 MHz (AV 500) in deuterated chloroform using tetramethylsilane as internal standard. The chemical shift values were recorded on δ scale. Elemental analysis was undertaken with Elemental Vario EL III Carlo Erba 1108 analyser. Syntheses of the target compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) were performed according to fig. 2 , through following steps. [39] :
Synthesis of potassium dithiocarbazinate (B)
Isonicotinic acid hydrazide (A; 14 g, 0.10 mol) was added to a solution of potassium hydroxide (8.4 g, 0.15 mol) in absolute ethanol (100 ml) and resulting content was stirred for 10-15 min at room temperature. After this, carbon disulphide (8 ml, 0.15 mol) and ethanol (50 ml) were added to the above mixture and stirred further for 15-16 h at room temperature till the complete precipitation of potassium dithiocarbazinate (B). Precipitate thus obtained was filtered. After evaporating to dryness under reduced pressure, the residue was purified by column chromatography, eluting with methanol:ethyl acetate (30:70 v/v).
Synthesis of 4-amino-5-pyridin-4-yl-1,2,4-triazole-3-thiol (C) [40] :
Potassium dithiocarbazinate (B; 21 g, 0.079 mol), hydrazine hydrate (12 ml, 0.24 mol) and distilled water (50 ml) were placed in a round bottom flask and refluxed for 4 h, after which the reaction mixture was cooled to room temperature, diluted with cold distilled water (50 ml) and acidified with dilute acetic acid to obtain a light yellow precipitate, which, was then filtered, washed with cold distilled water, dried and recrystallized with methanol to get white crystals of 4-amino-5-pyridin-4-yl-1,2,4-triazole-3-thiol (C).
Synthesis of target compounds (1-12) [41] :
A mixture of compound (C; 1g, 0.005 mol) and equimolar quantity of respective aldehydes in methanol (50-70 ml) was heated until a clear solution was obtained. This solution in presence of a few drops of concentrated hydrochloric acid was then refluxed for 3-4 h. After this reaction mixture was kept overnight at room temperature to obtain the corresponding product, which was then filtered. Evaporation and purification on silica-gel column (methanol/methylene dichloride 12:88 v/v) yielded compounds 1-12. 
4-Ethylideneamino

4-Butylideneamino-5-pyridin-4-yl-4H-[1,2,4] triazole -3-thiol (3):
Yield 63 % as off white solid, melting point >229°, IR (KBr, cm 
4-[(4-Fluoro-benzylidene)-amino]-5-pyridin-4-yl-4H-[1,2,4]triazole-3-thiol (5):
Yield 70 % as orange red solid, melting point 240-242°, IR (KBr, cm 
4-[(4-Bromo-benzylidene)-amino]-5-pyridin-4-yl-4H-[1,2,4]triazole-3-thiol (7):
Yield 
4-[(4-Methyl-benzylidene)-amino]-5-pyridin-4-yl-4H-[1,2,4]triazole-3-thiol (8):
Yield 75 % as yellow crystalline solid, melting point 160-162°, IR (KBr, cm 
4-[(4-
4-(3-Phenyl-allylideneamino)-5-pyridin-4-yl-4H-[1,2,4]triazole-3-thiol (12):
Yield 66 % as brownish yellow crystals, melting point >243°, IR (KBr, cm 
Biological evaluation:
All the newly synthesized 1,2,4-triazoles were assayed in vitro for antitubercular activity against M. tuberculosis H37Rv and clinical isolates: S, H, R and E resistant M. tuberculosis. In case of antimycobacterial activity, percentage reduction in relative light units (RLU) was calculated using luciferase reporter phage (LRP) assay using INH as a reference standard. Synthesized compounds were also tested against a representative panel of bacterial and fungal pathogens by the broth microdilution minimal inhibitory concentration (MIC) method.
LRP assay [42,43] :
Fifty-microliter bacterial suspension equivalent to McFarland's No.2 standard was added to 400 ml of G7H9 with and without the test compound. For each sample, two drug-free controls and two drug concentrations were prepared and this setup was incubated for 72 h at 37°. After incubation 50 ml of the high titer LRP (phAE129) and 400 ml of 0.1 M CaCl 2 were added to all the vials and this setup was incubated at 37° for 4 h. After incubation, 100 ml of the mixture was taken from each tube into a luminometer cuvette and equal amount of working D-luciferin (0.3 mM in 0.05 M sodium citrate buffer, pH 4.5) solution was added. The RLU was measured after 10 s of integration in the luminometer (Monolight 2010). Duplicate readings were recorded for each sample and the mean was calculated. The percentage reduction in the RLU was calculated for each test sample and compared with the control. The experiment was repeated when the mean RLU of the control was less than 1000.
Antibacterial and antifungal screening:
The in vitro antimicrobial activity of all the compounds and standard drugs were assessed against two representatives of Ampicillin and norfloxacin were used as standard antibacterial drugs, whereas fluconazole was used as standard antifungal drug.
Primary inoculation of bacteria was done into Mueller-
Hinton agar for overnight growth to produce a number of colonies, which were then directly suspended in saline solution until the turbidity matched the turbidity of the McFarland standard (10 8 CFU ml -1 ), i.e., inoculum size for test strain was adjusted to 10 8 colony forming unit (CFU)/ml per well by comparing the turbidity (turbidimetric method). Similar procedure was adopted for fungi with Sabouraud dextrose broth. Dimethyl sulfoxide (DMSO) was used as diluents to get desired concentration of the synthesized compounds and standard drugs. Each compound and standard drugs were diluted to obtain 500 μg/ml concentrations, as a stock solution. Stock solution was further progressively diluted with the test medium and required concentrations were obtained for primary and secondary screening. In primary screening 500, 250 and 125 μg/ml concentrations of the synthesized compounds were tested. The active compounds found in this primary screening were further diluted and tested against the corresponding microorganism. Each test tube was then put for incubation at 37° for 24 h for bacteria and 48 h for fungi. Growth or a lack of growth in the tubes containing the antimicrobial agent was determined by comparison with the growth control, indicated by turbidity. The lowest concentration that completely inhibited visible growth of the organism was recorded as the MIC (μg/ml). A set of tubes containing only seeded broth and the DMSO controls were maintained under identical conditions so as to make sure that the solvent had no influence on strain growth. The interpretation of the results was based on fluconazole for the fungi and also on ampicillin and norfloxacin for bacterial pathogens. The results (MIC, μg/ml) obtained are summarized in Table 2 .
RESULTS AND DISCUSSION
INH (A) was first reacted with potassium hydroxide in absolute ethanol by simple stirring the mixture at room temperature. Carbon disulphide and ethanol were then added to the above mixture and resulting content was stirred further for 15-16 h at room temperature to obtain potassium dithiocarbazinate (B). After this a mixture of potassium dithiocarbazinate (B), hydrazine hydrate and distilled water was refluxed for approximately 4 h and then cooled to room temperature, diluted with cold distilled water and acidified with dilute acetic acid to obtain a light-yellow precipitate, which appeared as white crystals of 4-amino-5-pyridin-4-yl-1,2,4-triazole-3-thiol (C) after filtration, washing with cold water, drying and recrystallization. Finally, a mix of compound (C) and equimolar quantity of respective aldehyde in methanol was then refluxed for 3-4 h in presence of concentrated hydrochloric acid and kept overnight to obtain the corresponding products (1-12) .
Structures of compounds 1-12 were confirmed by IR, NMR spectroscopy data as well as their distinct R f values in TLC analysis. As the desired target compounds (1-12) are formed, strong band of -NH 2 stretch (single band in the range 3350-3500 cm -1 ) is disappeared and -C=N signal appear in the ranges 1605-1630 cm -1 in their corresponding IR spectra. Similarly characteristic proton NMR signal near 7.5 for 1H of CH of aldimine further confirm the formation of the target compounds. Number of signals in 13 C NMR spectra of compounds 1-12 was measured with their corresponding chemical shift values to characterize the formation of compounds. Compound 1 provided nine 13 C NMR signals with characteristics 163.8 for C of N=CH and 9.33 for C of CH 3 attached to aldimine carbon. Similarly, compound 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 given 10, 11, 14, 14, 14, 14, 15, 15, 14, 17 and 16 13 C NMR signals along with characteristic range of aldimine C signal, which is given with individual compounds in experimental section.
All the newly synthesized compounds were assayed in vitro for antitubercular activity against M. tuberculosis H37Rv and clinical isolates: S, H, R and E resistant M. tuberculosis. In case of antimycobacterial activity, percent reduction in RLU was calculated using LRP assay at two different concentrations (50 and 100 μg/ml) using INH as a reference standard and the observed percent inhibition has been tabulated in Table 1 . Compound is considered to be an antimycobacterial, if 50 % reduction in the RLU was observed when compared to the control using a luminometer.
At 50 µg/ml concentration, compounds 4, 5, 6, 8, 10 and 12 were found to be active, while at higher concentration (100 µg/ml), these compounds showed higher activities against M. tuberculosis H37Rv. Among these, compound 8 and 12 at 100 µg/ml exhibited greater reduction in RLU than the reference standard INH, while compound 5 at 100 µg/ml displayed reduction in RLU comparable to that of the INH. Most active compounds 8, 12 and 15 of this series bear 4-CH 3 -C 6 H 4 -, CH=CH-C 6 H 5 -and 4-F-C 6 H 4 -substituents, respectively at 4 th position in the triazole ring.
In case of clinical isolates: S, H, R, and E resistant M. tuberculosis, <50 % reduction in RLU was only seen with compounds 8, 12 and 5 at 100 µg/ml concentration, however, compounds 4, 5, 8, 12 at 50 µg/ml and 3, 4, 6, 7, 9 at 100 µg/ml showed higher reduction in RLU than INH and hence exhibited better antitubercular activity than the standard drug. Three compounds, 8, 12 and 5 found to be most potent among the series against H37Rv as well as S, H, R and E resistant M. tuberculosis strains. Higher potencies of these compounds suggest that substituents at 4 th position contributing pharmacokinetically toward antitubercular activity. This has been stated because compounds 12 and 8 seems to be highly lipophilic due to contribution by styryl and tolyl components respectively, while compound 5 bears 4-F-C 6 H 4 -at 4 th position that is comparatively polar in nature.
All the newly synthesized compounds were assayed in vitro for antibacterial and antifungal activity against a representative panel of bacterial and fungal pathogens. In primary screening 500, 250 and 125 μg/ml concentrations of the synthesized compounds were tested. The active compounds found in this primary screening were further diluted and tested against the corresponding microorganism to obtain their MICs, where the lowest concentration that completely inhibited visible growth of the organism was recorded as MIC (μg/ml).
The obtained results (Table 2) revealed that all of the synthesized compounds exhibited potent antibacterial activities against both Gram-positive strains. In case of Staphylococcus aureus, compound 5 (MIC=12.5 μM), 6 (MIC=14.1 μM), 9 (MIC=18.75 μM), 10 (MIC= 13.3 μM) and 11 (MIC=15.6 μM) exhibited MICs as good as ampicillin (MIC=10.2 μM). Interestingly, the same compounds i.e. 5, 6, 9, 10 and 11 were shown to be most active against Bacillus subtilis, where compound 5 gave better antiB. subtilis activity (MIC=10.2 μM) than ampicillin (MIC=10.9 μM). Antibacterial activities of the compounds improve as the electron withdrawing or donating capacity of the substituent on phenyl ring at fourth position of 1,2,4-triazole increase.
Prepared compounds showed lower antibacterial potencies against Gram-negative bacteria as compared to Gram-positive bacterial strains. Compounds Many significant facts were observed on analysing the effect of the substituents on the antibacterial activity of the synthesized compounds. Antibacterial activity of the compounds has been improved by the substitution of the more electron withdrawing group on the phenyl ring at the fourth position of 1,2,4-triazoles. The polar nature of the substituent on the phenyl ring at the fourth position converted the compounds into less lipophilic character. The addition of the benzyl substitution on the 1,2,4-triazoles potentiates antibacterial activity. Substitution of -F on the phenyl group potentiate the activity as compared to the ampicillin. Table 2 represent all the data of antibacterial and antifungal activity correlated with this conclusion. Substitution of methyl, ethyl, propyl and phenyl at the fourth position diminished the antibacterial activity. As far as antitubercular activity is concern substitution of more electron withdrawing group at the fourth position on the phenyl ring of the 1,2,4-triazoles is favourable for the activity. Compound 5 with 4-fluorophenyl group at position 4 of 1,2,4-triazoles exhibited better activity than phenyl or chlorophenyl substitutions. This is due to more electronegativity of fluorine than chloro. Substitution of methyl on 4 th position of phenyl ring as in compound 8 has shown better activity profile as compared to electron donating group with less steric hindrance effect. The group contributes to positive inductive effect to the benzyl electron cloud leading more active electron cloud system, which has led to a positive denotable effect. Compounds with methoxy (compound 9), tri-methoxy (compound 11) or nitro (compound 10) group on phenyl ring exhibited lesser activity may be due to high steric and moderate electron withdrawing effect. Higher potencies of these compounds suggest that substituents at 4 th position also contributes pharmacokinetically toward antitubercular activity because compounds 12 and 8 seems to be highly lipophilic due to contribution of styryl and tolyl components, respectively, while compound 5 bears 4-fluorophenyl at 4 th position is comparatively polar in nature.
In the present investigation, 12 different 1,2,4-triazoles were synthesized and evaluated for 
